ViiV Healthcare

Results: 50



#Item
1Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio - ViiV Healthcare acquires exclusive global rights to HIV integrase inhibitor portfolio, including dolutegrav

Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio - ViiV Healthcare acquires exclusive global rights to HIV integrase inhibitor portfolio, including dolutegrav

Add to Reading List

Source URL: shionogi616.tew-staging.com

Language: English - Date: 2014-11-03 11:26:24
2Shionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference Positive Antiviral Responses Demonstrated in Interim 16 Week Analysis from SPRING-1 S

Shionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference Positive Antiviral Responses Demonstrated in Interim 16 Week Analysis from SPRING-1 S

Add to Reading List

Source URL: shionogi616.tew-staging.com

Language: English - Date: 2014-11-03 11:26:22
3Data from the FLAMINGO Phase IIIb/IV Study of the Integrase Inhibitor Tivicay® (dolutegravir), Disclosed by ViiV Healthcare Osaka, Japan, September 13, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: I

Data from the FLAMINGO Phase IIIb/IV Study of the Integrase Inhibitor Tivicay® (dolutegravir), Disclosed by ViiV Healthcare Osaka, Japan, September 13, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: I

Add to Reading List

Source URL: shionogi616.tew-staging.com

Language: English - Date: 2014-11-03 11:26:11
4Interim Results from SAILING Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, March 7, Shionogi & Co., Ltd. (Head Office: Osaka; Preside

Interim Results from SAILING Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, March 7, Shionogi & Co., Ltd. (Head Office: Osaka; Preside

Add to Reading List

Source URL: shionogi616.tew-staging.com

Language: English - Date: 2014-11-03 11:26:24
5ViiV Healthcare Receives EU marketing authorization for Triumeq®, a Single-pill Regimen Containing the Integrase Inhibitor “Dolutegravir” Osaka, Japan, September 4, Shionogi & Co., Ltd. (Head Office: Osaka; P

ViiV Healthcare Receives EU marketing authorization for Triumeq®, a Single-pill Regimen Containing the Integrase Inhibitor “Dolutegravir” Osaka, Japan, September 4, Shionogi & Co., Ltd. (Head Office: Osaka; P

Add to Reading List

Source URL: shionogi616.tew-staging.com

Language: English - Date: 2015-01-27 14:49:56
6

PDF Document

Add to Reading List

Source URL: shionogi616.tew-staging.com

Language: English - Date: 2014-11-03 11:26:09
7Microsoft Word - 20130218_FDA Priority Review Designation for DTG_E_Final

Microsoft Word - 20130218_FDA Priority Review Designation for DTG_E_Final

Add to Reading List

Source URL: shionogi616.tew-staging.com

Language: English - Date: 2014-11-03 11:26:24
8Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor Phase III Treatment-naïve and Treatment-experienced Trials Underway for S/GSK1349572 (‘572)

Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor Phase III Treatment-naïve and Treatment-experienced Trials Underway for S/GSK1349572 (‘572)

Add to Reading List

Source URL: shionogi616.tew-staging.com

Language: English - Date: 2014-11-03 11:26:21
9ANNUAL REPORT 2014 MEDICINES PATENT POOL WELCOME TO THE MEDICINES PATENT POOL ANNUAL REPORT 2014

ANNUAL REPORT 2014 MEDICINES PATENT POOL WELCOME TO THE MEDICINES PATENT POOL ANNUAL REPORT 2014

Add to Reading List

Source URL: www.medicinespatentpool.org

Language: English - Date: 2015-05-20 04:19:35
10Data from VIKING-3 Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, November 14, Shionogi & Co., Ltd. (Head Office: Osaka; President & C

Data from VIKING-3 Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, November 14, Shionogi & Co., Ltd. (Head Office: Osaka; President & C

Add to Reading List

Source URL: shionogi616.tew-staging.com

Language: English - Date: 2014-11-03 11:26:18